Lorazepam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Lorazepam: From Anxiety and Seizure Disorders to Trigeminal Nerve Neoplasm
One-Sentence Summary
Lorazepam is a benzodiazepine originally used for anxiety disorders and seizure conditions, including status epilepticus. The TxGNN model predicts it may be effective for trigeminal nerve neoplasm, but no clinical trials and no publications currently support this prediction. The score comes from the graph model alone, and the other predicted indications show stronger evidence only where they overlap with lorazepam's existing seizure use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorder, status epilepticus, absence epilepsy, Lennox-Gastaut syndrome (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Trigeminal nerve neoplasm |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, lorazepam is a positive allosteric modulator of the GABA-A receptor. It enhances inhibitory signalling, which produces anxiolytic, sedative and anticonvulsant effects.
For the top-ranked prediction, trigeminal nerve neoplasm, no mechanistic rationale is evident. Enhanced GABAergic inhibition has no known antitumour activity. At most, lorazepam could play a supportive role, such as managing anxiety or procedural sedation in patients with this tumour. That would not be a new disease-modifying indication. The high TxGNN score reflects graph-based association only.
Other predictions in the list show a different pattern. Several are reflex or unusual seizure types (reading, eating, startle, thinking, micturition-induced, orgasm-induced and audiogenic seizures) and one is an acute encephalopathy with seizures. These fall within lorazepam's existing anticonvulsant use, so they are extensions of a known indication rather than distinct repurposing opportunities. Insomnia is biologically plausible because of the sedative-hypnotic effect, but its repurposing value is low, since it overlaps with the existing anxiolytic and sedative profile and guidelines discourage long-term benzodiazepine use for it.
Clinical Trial Evidence
Currently no related clinical trials registered for trigeminal nerve neoplasm. No registered trials were found for any of the other top-10 predicted indications either.
Literature Evidence
Currently no related literature available for trigeminal nerve neoplasm.
For reference, the next-ranked prediction, insomnia, has the following most relevant publications:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3280615 | 1988 | Clinical comparative study | J Clin Pharmacol | Double-blind crossover in 8 chronic insomniacs; 2 mg lorazepam performed better than 30 mg flurazepam on most sleep parameters |
| 10220122 | 1999 | Clinical study | Int Clin Psychopharmacol | Compared lorazepam 0.5 mg three times daily with 1.5 mg at bedtime in primary insomnia |
| 30625122 | 2018 | Review | Med Lett Drugs Ther | Review of drugs for chronic insomnia |
| 36692463 | 2023 | Meta-analysis | Acta Pharm | Tranquilizer use in elderly patients with chronic non-communicable diseases: dose, outcomes and adverse effects |
These studies are small and old, and they concern a different indication from the top prediction.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN00967P | LORANS 1 TABLET 1 mg | Tablet | Not stated in the compiled records |
| SIN03452P | APO-LORAZEPAM TABLET 1 mg | Tablet | Not stated in the compiled records |
| SIN03708P | APO-LORAZEPAM TABLET 0.5 mg | Tablet | Not stated in the compiled records |
All three are valid single-ingredient oral tablet licences.
Safety Considerations
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for safety information.
- Knowledge-graph contraindication signals (not label text): liver failure, liver disease, hepatic encephalopathy, kidney disease, respiratory failure, sleep apnoea syndromes, congenital central hypoventilation syndrome, open-angle and angle-closure glaucoma, porphyria, substance-related disorders and dependence, and gallbladder disease. Anxiety disorder, neurotic disorder and dysthymic disorder also appear in this list. That is notable, because anxiety is also an indication, so this entry needs clarification.
- Drug Interactions: 100 interactions were recorded. The main ones are:
- Major: morphine, and liposomal morphine (additive central nervous system and respiratory depression).
- Moderate: bupropion, dronabinol, nabilone, metoclopramide, opium, sibutramine, teduglutide.
- Minor: antacids (aluminium hydroxide, magnesium oxide, magnesium hydroxide, magnesium carbonate, calcium carbonate, magaldrate).
- Other literature notes tolerance, dependence, next-day impairment and propylene glycol toxicity with intravenous use.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction, trigeminal nerve neoplasm, rests on a graph score alone. There is no mechanistic basis, no trial and no literature, so the evidence level is L5. Among the other top-10 predictions, the better-supported ones are either extensions of existing seizure use or low-value overlaps (insomnia, L3), so none presents a distinct repurposing case.
To proceed, the following is needed:
- A mechanistic or clinical rationale for any antitumour or disease-modifying role in trigeminal nerve neoplasm, if that direction is to be pursued
- Package insert warnings and contraindications from the HSA records (a blocking gap for safety screening)
- Detailed mechanism of action data
- Singapore approved-indication text for the three licences
- A clear statement of whether any seizure-type prediction is a true new indication or falls under the existing seizure label
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.